Exopharm

Exopharm's products include Plexaris, exosomes derived from human platelets, and Exomeres, exosomes from stem cells.Exosomes are extracellular vesicles involved in cell-cell communication and transmission of disease states through transfer of protein, RNA, lipids and microRNA. Exosomes are thought to mediate some of the regenerative effects of stem cells and provide a cell-free therapeutic agent with therapeutic benefits.The company aims to treat diseases such as dry Age Related Macular Degeneration (AMD), tendinopathy, arthritis, cardiac repair, neurodegeneration and aging.

Introduction to Exopharm.

Exopharm's proprietary LEAP Technology provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells and other sources which claims to address existing limitations in exosome purification processes. Exopharm's technology is designed for the manufacture of a proprietary exosome product at clinical and then pharmaceutical grade and scale.

The Stem Cell Exomere Program is a partnership between RoosterBio and Exopharm to develop and implement a standardized, scalable, commercially-viable biomanufacturing process and a cGMP-compliant Exomere product (exosomes) for regenerative medicine applications.